


HEDGEYE

# Hedgeye Health Care: Weekly Sector Distillation

MicroQuads & Estimate Revision Trends

For the week ending Oct. 1, 2021

October 4, 2021



## Hedgeye Health Care

Tom Tobin, Managing  
Director, Health Care

Ttobin@Hedgeye.com  
@HedgeyeHC

William McMahon, Analyst,  
Health Care

WmcMahon@Hedgeye.com  
@HedgeyeMed

Justin Venneri, Director,  
Primary Research

Jvenneri@hedgeye.com  
@HedgeyeJVenneri

## DISCLAIMER

The preceding has been presented for informational purposes only. None of the information contained herein constitutes an offer to sell, or a solicitation of an offer to buy any security or investment vehicle, nor does it constitute an investment recommendation or legal, tax, accounting or investment advice by Hedgeye or any of its employees, officers, agents or guests. This information is presented without regard for individual investment preferences or risk parameters and is general, non-tailored, non-specific information. This content is based on information from sources believed to be reliable. Hedgeye is not responsible for errors, inaccuracies or omissions of information. The opinions and conclusions contained in this report are those of the individual expressing those opinions or conclusion and are intended solely for the use of Hedgeye's subscribers and the authorized recipients of the content. All investments entail a certain degree of risk and financial instrument prices can fluctuate based on several factors, including those not considered in the preparation of the content. Consult your financial professional before investing.

## TERMS OF USE

The information contained herein is protected by United States and foreign copyright laws and is intended solely for the use of its authorized recipient. Access must be provided directly by Hedgeye.

Redistribution or republication is strictly prohibited. For more detail please refer to the Terms of Service at [https://www.hedgeye.com/terms\\_of\\_service](https://www.hedgeye.com/terms_of_service).

## MICROQUAD RESULTS

While we have up to five (5) years of data on the securities in the MicroQuads model, not all securities in the model have five years of trading history, and while we make every effort to assure the accuracy of the data, we cannot guarantee its accuracy. The methodology used to arrive at the results displayed herein is proprietary to Hedgeye and involves aggregating the actual historical results for each security while it "resides" in the appropriate MicroQuad over the defined periods of time. These results do not include any consideration for trading costs, commissions, or other factors that could impact results, we make no representations or warranties that past results will or can be repeated, and the data have not been verified by a third-party.

## PERFORMANCE MONITOR FORWARD/PROSPECTIVE PRICE CHANGES

The data for each security are based on historic price performance and average forward returns and are not a guarantee of future performance. We make every effort to assure the accuracy of the calculations and forecasts; however, we cannot guarantee their accuracy or that performance will be repeated.

# Health Care Position Monitor

For Week of October 4, 2021

Best Ideas - Longs					Best Ideas - Shorts						
LONG		Price	Mkt Cap (\$B)	Trend	Tail	SHORT		Price	Mkt Cap (\$B)	Trend	Tail
<b>Active Longs</b>											
NTRA	Natera, Inc.	\$ 126.36	\$11.9B	✓	✓	TDOC	Teladoc Health, Inc.	\$ 143.16	\$22.8B	✗	✗
AMN	AMN Healthcare Services, Inc.	\$ 112.11	\$5.3B	✓	✓	EXAS	Exact Sciences Corporation	\$ 108.15	\$18.6B	✗	✗
DGX	Quest Diagnostics Incorporated	\$ 154.77	\$18.9B	✓	✓	ARKG	ARK Genomic Revolution ETF	\$ 83.93	\$8.2B	✗	✗
EYE	National Vision Holdings, Inc.	\$ 58.88	\$4.8B	✓	✓						
ONEM	1Life Healthcare, Inc.	\$ 25.16	\$4.9B	✓	✓						
NEO	NeoGenomics, Inc.	\$ 48.32	\$5.9B	✓	✓						
DRIO	DarioHealth Corp.	\$ 14.37	\$0.2B	✓	✓						
BFLY	Butterfly Network, Inc. Class A	\$ 12.54	\$2.1B	✓	✓						
ATIP	ATI Physical Therapy, Inc. Class A	\$ 3.53	\$0.7B	✓	✓						
<b>Long Bias</b>											
GDRX	GoodRx Holdings, Inc. Class A	\$ 46.98	\$14.8B			AMWL	American Well Corporation Class A	\$ 11.25	\$2.4B		
TXG	10x Genomics Inc Class A	\$ 163.49	\$14.8B			UHS	Universal Health Services, Inc. Class B	\$ 145.92	\$11.1B		
NVTA	Invitae Corp.	\$ 31.54	\$6.9B			ACHC	Acadia Healthcare Company, Inc.	\$ 61.22	\$5.5B		
GH	Guardant Health, Inc.	\$ 132.05	\$13.4B			ME	23andMe Holding Co Class A	\$ 8.34	\$0.8B		
<b>Short Bias</b>											

## Note

Best Idea Longs/Shorts are high conviction ideas that we've either presented a Black Book for already or have one in the works (similar to other Hedgeye teams). Bias Ideas are ones in which we've done the bulk of the work, but there may be another question we need to answer to move it over the line. All active positions are higher conviction than bias ideas. We rank active versus active and bias versus bias.


## Disclaimer

Hedgeye's "bias" represents Hedgeye's outlook on companies currently under Hedgeye's review, or for which timing is not right for greater coverage. Hedgeye may or may not provide further commentary on any or all companies represented on the bias and representation of a company on the bias does not forecast whether Hedgeye will or will not issue any additional material on that company.


# MicroQuad | Model vs Actual

HEDGEYE

## MicroQuad – Generic Growth Curve Progression



## MicroQuad - The Four Quadrants



# MicroQuad | Model vs Actual

HEDGEYE


## MicroQuad – Percentage Change

Average Performance (%)					
MicroQuad	1WK	1M	3M	6M	12M
1	-1.90	-3.62	-7.21	-1.74	26.36
2	0.36	0.08	-12.61	7.12	59.37
3	1.75	1.21	4.82	17.42	57.04
4	1.95	-0.87	-7.47	-5.13	8.05

Batting Average					
MicroQuad	1WK	1M	3M	6M	12M
1	0.402	0.460	0.478	0.497	0.503
2	0.442	0.480	0.482	0.499	0.510
3	0.469	0.479	0.509	0.528	0.527
4	0.451	0.429	0.461	0.470	0.497

Slugging Percentage					
MicroQuad	1WK	1M	3M	6M	12M
1	-0.763	-1.665	-3.444	-0.865	13.252
2	0.157	0.036	-6.081	3.551	30.261
3	0.818	0.578	2.451	9.191	30.077
4	0.879	-0.374	-3.442	-2.412	3.997


## MicroQuad – Actual Price Change vs Growth Curve



# Estimate Revision Trend | October 1, 2021

HEDGEYE

Revision trend rate of change pulling back a bit after 2Q21 inflection point




As of 10/1/2021 estimate trend slope has been fighting against the **Delta Variant** since late July 2021 and after finally turning positive against the COVID-comp during 2Q21 earnings season.

COVID cases are falling nationally and leaving a fewer number of hot spots across the United States. We've seen only a modest impact to broad measures of medical utilization as Delta Variant ramped and fell over the third quarter. We are expecting a solid 3Q21 earnings season.

# Estimate Trend | Down and then up again?

**Will 3Q21 bring a higher low? Looks like it might be heading for upside**



Consensus revenue estimates began to turn negative at the end of February 2021, coincident with the beginning of a slide in performance across our Health Care universe. The recovery since then has stalled.

**Looking to 3Q21 results with delta waning could lead to positive commentary on 3Q earnings call.**

# MicroQuad Screen | Oct 1, 2021



HEDGEYE

## MicroQuad1

ABT	LLY
AMED	MCK
AMGN	MRK
BDX	NEO
DGX	OPK
DOCS	PKI
ENSG	PRSC
EXAS	QDEL
FLGT	SYK
GKOS	TDOC
HOLX	TMO
LH	

## MicroQuad2

ABMD	PODD
CERN	RCM
CHNG	SGRY
CNMD	TFX
COO	TXG
HAE	
IART	
LHCG	
MDT	
NSTG	
NVTA	
OMCL	

## MicroQuad3

A	EHC	INOV	RGEN	ZTS
ABC	EYE	IQV	RMD	
ALGN	GH	ISRG	SEM	
ATRC	GMED	MEDP	STAA	
BAX	HCA	MMSI	STE	
BIO	HCAT	MOH	TECH	
BSX	HRC	MTD	TNDM	
CHE	HSKA	NTRA	TWST	
CRL	HUM	PCRX	UNH	
CVET	ICUI	PEN	VEEV	
DHR	IDXX	PHR	WAT	
DXCM	ILMN	Q	WST	

## MicroQuad4

ABBV
AMN
ANTM
JNJ
MASI
MRNA
OPCH
VRTX

# MicroQuad 2 Screen

HEDGEYE

## High multiple, high beta, small cap, large pull backs

Ticker	Name	Price	MicroQuad 2											Sales MicroQuad								
			1W	1M	3M	EV	MCAP	Beta	Days to Cover	Sales Corr	Sales	EBITDA	EPS	J-21	A-21	S-21	O-21	N-21	D-21	J-22	F-22	M-22
ABMD	ABIOMED, Inc.	\$325.52	-7.16	-10.56	4.03	14,133	14,673	0.80	4.97	0.60	1,121	296	\$4.44	2	2	2	2	3	3	3	3	3
CERN	Cerner Corporation	\$70.52	-3.62	-7.64	-10.15	22,306	20,792	0.39	8.86	0.59	6,025	2,033	\$3.55	3	3	2	2	2	2	2	3	3
CHNG	Change Healthcare, Inc.	\$20.94	-3.01	-4.08	-8.96	11,559	6,565	0.11	9.96	0.56	3,554	1,094	\$1.61	2	2	2	2	2	2	2	3	3
CNMD	CONMED Corporation	\$130.83	-0.07	-0.39	-5.71	5,020	3,896	1.02	10.44	0.93	1,097	230	\$3.63	2	2	2	2	2	3	3	3	3
COO	Cooper Companies, Inc.	\$413.31	-5.92	-8.30	2.56	22,534	20,554	0.94	6.06	0.93	3,087	1,039	\$14.53	3	3	2	2	3	3	3	3	3
HAE	Haemonetics Corporation	\$70.59	1.38	12.49	4.22	4,279	3,669	-0.04	4.15	0.56	1,027	280	\$2.88	3	2	2	2	2	2	3	3	3
IART	Integra LifeSciences Holdings Corporation	\$68.48	-5.32	-8.97	-0.94	7,193	5,884	0.99	11.06	0.64	1,615	429	\$3.32	2	2	2	2	2	2	3	3	3
LHCG	LHC Group, Inc.	\$156.91	-2.47	-15.98	-23.26	4,915	4,851	0.16	4.92	0.79	2,389	322	\$6.78	2	2	2	2	2	2	3	3	3
MDT	Medtronic Plc	\$125.35	-4.05	-6.09	-0.62	188,230	171,335	0.94	2.57	0.68	33,769	10,410	\$5.95	2	2	2	2	2	2	3	3	3
NSTG	NanoString Technologies, Inc.	\$48.01	-6.61	-17.51	-24.69	2,017	2,175	-0.28	14.30	0.91	175	-69	-\$2.21	2	2	2	2	2	2	3	3	3
NVTA	Invitae Corp.	\$28.43	-11.68	-4.05	-15.39	7,776	6,231	0.67	8.60	0.85	626	-410	-\$2.50	2	2	2	2	3	3	3	3	3
OMCL	Omnicell, Inc.	\$148.43	-5.03	-4.41	-0.17	7,138	6,663	1.31	12.74	0.95	1,229	273	\$4.02	3	2	2	2	2	2	3	3	3
PODD	Insulet Corporation	\$284.23	-2.19	-4.56	2.02	19,414	19,652	0.37	7.69	0.98	1,251	242	\$1.26	3	3	2	2	2	2	3	3	3
RCM	R1 RCM Inc	\$22.01	1.76	11.61	-2.00	7,692	6,294	0.45	4.61	0.86	1,638	388	\$0.55	2	2	2	2	3	3	3	3	3
SGRY	Surgery Partners, Inc.	\$42.34	-8.34	-13.94	-35.06	6,940	3,720	1.64	5.12	0.51	2,368	354	\$0.27	3	3	4	2	2	2	3	3	3
TFX	Teleflex Incorporated	\$376.55	-3.28	-4.78	-7.45	20,227	17,937	0.97	2.31	0.93	2,951	918	\$14.18	2	2	2	2	2	2	3	3	3
TXG	10x Genomics Inc Class A	\$145.58	-8.17	-17.25	-23.35	15,227	13,027	0.33	5.11	0.91	634	7	-\$0.27	2	2	2	2	2	2	2	2	3

The MicroQuad 2 long screen stocks appear dominated by Tools companies and Med Tech. With rising probability of Macro Quad 2 emerging in 4Q21, the smaller market cap, high multiple, and high beta names that have fallen the most look like good candidates for trading longs if the fundamentals check out.

# MicroQuad 3 Screen

Slowing, with some deteriorating further in 4Q21

Ticker	Name	Price	1W	1M	3M	EV	MCAP	Beta	Days to Cover	Sales Corr	Sales	EBITDA	EPS	J-21	A-21	S-21	O-21	N-21	D-21	J-22	F-22	M-22
A	Agilent Technologies, Inc.	\$157.53	-8.82	-10.22	6.59	49,349	47,222	0.79	2.59	0.92	6,713	1,902	\$4.74	3	3	3	3	4	4	4	1	1
ABC	AmerisourceBergen Corporation	\$119.45	-2.53	-2.26	2.59	29,950	24,895	0.88	2.91	0.78	236,403	3,419	\$10.55	3	3	3	3	4	4	4	4	1
ALGN	Align Technology, Inc.	\$665.43	-8.48	-6.15	7.51	51,736	52,310	1.02	3.71	0.89	4,570	1,389	\$12.75	3	3	3	3	3	3	3	3	3
ATRC	AtriCure, Inc.	\$69.55	-6.46	-5.53	-14.17	3,057	3,201	1.06	5.27	0.82	309	-5	-\$1.08	2	2	3	3	3	3	3	3	3
BAX	Baxter International Inc.	\$80.43	-0.45	5.52	-1.28	44,914	40,638	0.58	1.72	0.79	13,079	3,264	\$3.86	3	3	3	4	4	4	4	1	1
BIO	Bio-Rad Laboratories, Inc. Class A	\$745.95	-6.45	-7.31	13.42	21,420	22,069	0.24	3.47	0.92	2,829	636	\$13.67	4	3	3	3	4	4	4	4	4
BSX	Boston Scientific Corporation	\$43.39	-3.58	-3.90	0.07	69,370	62,365	0.97	3.68	0.91	12,740	3,621	\$1.80	2	2	3	3	3	3	3	3	2
CHE	Chemed Corporation	\$465.12	-1.04	-2.43	-3.60	7,415	7,202	0.27	3.30	0.98	2,205	466	\$19.36	1	4	3	4	4	4	4	1	1
CRL	Charles River Laboratories International, Inc.	\$412.67	-9.31	-7.03	10.74	24,200	21,000	1.25	1.51	0.89	3,887	1,017	\$11.36	3	3	3	3	4	4	4	1	1
CVET	Covetrus, Inc.	\$18.14	-9.66	-19.70	-32.89	3,396	2,543	0.94	5.03	0.55	4,838	272	\$1.05	2	2	3	3	3	3	3	3	3
DHR	Danaher Corporation	\$304.44	-6.33	-6.08	11.84	238,887	215,826	0.52	2.79	0.95	29,904	10,079	\$9.75	3	3	3	4	4	4	4	1	1
DXCM	DexCom, Inc.	\$546.86	-4.52	3.29	28.12	54,081	53,204	0.78	7.27	0.96	2,786	538	\$3.23	1	2	3	3	3	3	4	4	1
EHC	Encompass Health Corporation	\$75.04	-1.72	-4.35	-5.92	11,139	7,351	0.62	3.96	0.84	5,495	1,104	\$4.55	3	3	3	3	3	3	3	2	2
EYE	National Vision Holdings, Inc.	\$56.77	-5.84	-5.35	10.94	5,924	4,534	1.20	11.08	0.50	2,192	286	\$1.35	2	2	2	3	3	3	3	3	4
GH	Guardant Health, Inc.	\$125.01	-3.33	-1.78	-1.45	10,498	10,891	-1.22	6.54	0.81	469	-331	-\$3.36	2	3	3	3	3	3	2	2	2
GMED	Globus Medical Inc Class A	\$76.62	-5.35	-6.10	-2.51	7,720	6,186	1.51	2.64	0.89	1,019	361	\$2.17	2	2	2	3	3	3	3	3	3
HCA	HCA Healthcare Inc	\$242.72	-5.01	-4.06	14.58	117,905	79,328	0.93	2.82	0.86	59,855	12,537	\$17.61	2	3	3	3	3	3	4	4	1
HCAT	Health Catalyst, Inc.	\$50.01	-7.56	-8.42	-11.50	2,159	2,517	1.03	13.53	0.84	277	-2	-\$0.34	2	3	3	3	3	3	3	3	3
HRC	Hill-Rom Holdings, Inc.	\$150.00	-0.24	3.04	29.88	11,478	9,877	0.18	0.50	0.86	3,062	714	\$6.43	3	3	3	3	3	3	2	2	2
HSKA	Heska Corporation	\$258.54	-3.11	-2.55	9.55	2,449	2,741	0.66	4.58	0.90	281	38	\$0.66	3	3	3	4	4	4	4	1	1
HUM	Humana Inc.	\$389.15	-3.06	-4.01	-13.06	54,455	50,316	0.63	2.16	0.89	89,981	4,724	\$23.78	1	2	3	3	4	4	4	4	4
IQUI	ICU Medical, Inc.	\$233.38	-4.80	17.07	12.12	4,652	4,964	1.06	1.04	0.71	1,285	279	\$7.57	3	3	3	3	3	3	3	3	3
IDXX	IDEXX Laboratories, Inc.	\$621.90	-8.89	-7.70	-2.67	54,852	53,086	0.80	3.14	0.95	3,456	1,115	\$9.19	3	3	3	3	3	3	3	4	4
ILMN	Illumina, Inc.	\$405.61	-6.37	-11.28	-13.82	56,191	57,923	0.65	3.81	0.91	4,681	1,466	\$6.07	3	3	3	3	3	3	3	2	2
INOV	Inovalon Holdings, Inc. Class A	\$40.29	-0.25	-1.37	18.85	6,912	2,932	-0.05	1.12	0.74	845	301	\$0.87	3	3	3	3	3	3	3	2	2
IQV	IQVIA Holdings Inc	\$239.54	-8.67	-7.77	-3.08	57,799	46,284	0.92	5.47	0.92	14,435	3,190	\$9.72	3	3	3	3	4	4	4	1	1
ISRG	Intuitive Surgical, Inc.	\$994.15	-4.85	-5.64	7.19	118,358	120,121	1.15	2.65	0.93	6,213	2,625	\$15.95	3	3	3	3	3	3	4	1	3

Guardant has been attracting our deepening skepticism despite what should be a tailwind to cancer testing. Their decision to split off the screening technology is strange and made stranger by the rumor they were considering acquiring NEO this past weekend. In Macro Quad 2, GH will have a factor tailwind and they've already cautioned about 2H21 growth.

# MicroQuad 3 Screen Con't

Slowing, with some deteriorating further in 4Q21

MicroQuad 3														Sales MicroQuad									
Ticker	Name	Price	1W	1M	3M	EV	MCAP	Beta	Days to Cover	Sales Corr	Sales	EBITDA	EPS	J-21	A-21	S-21	O-21	N-21	D-21	J-22	F-22	M-22	
MEDP	Medpace Holdings, Inc.	\$189.28	-3.05	3.80	6.12	7,167	7,007	1.25	3.35	0.91	1,306	248	\$4.92	4	2	2	3	3	4	4	4	4	
MMSI	Merit Medical Systems, Inc.	\$71.80	-1.82	0.04	11.23	4,454	4,081	0.72	8.06	0.55	1,108	230	\$2.33	1	2	3	3	3	3	3	3	3	
MOH	Molina Healthcare, Inc.	\$271.31	-4.04	0.95	5.96	13,600	15,856	1.08	4.88	0.87	28,580	1,427	\$15.92	3	3	3	3	4	4	4	4	4	
MTD	Mettler-Toledo International Inc.	\$1,377.36	-11.91	-11.30	-0.27	34,205	32,130	1.02	4.43	0.89	3,788	1,157	\$35.16	3	3	3	3	4	4	4	1	1	
NTRA	Natera, Inc.	\$111.44	-9.79	-5.90	-3.98	9,704	10,540	1.00	11.06	0.94	718	-384	-\$4.53	3	3	3	3	3	4	4	4	1	
PCRX	Pacira Biosciences, Inc.	\$56.00	-3.43	-5.55	-6.64	2,501	2,533	0.99	20.18	0.72	606	257	\$3.70	2	2	3	3	3	4	4	1	1	
PEN	Penumbra, Inc.	\$266.50	-5.69	-3.07	-3.55	9,772	9,624	0.48	7.86	0.91	822	89	\$1.40	3	3	3	3	3	3	3	3	2	
PHR	Phreesia, Inc.	\$61.70	-5.34	-13.77	-0.48	2,634	3,079	0.79	2.39	0.90	227	-30	-\$1.49	3	3	3	3	3	3	3	3	2	
Q	IQVIA Holdings Inc	\$239.54	-8.67	-7.77	-3.08	57,799	46,284	0.92	5.47	0.92	14,435	3,190	\$9.72	3	3	3	3	4	4	4	1	1	
RGEN	Repligen Corporation	\$288.99	-10.86	2.12	44.70	15,563	15,482	0.86	5.36	0.96	724	238	\$2.97	3	3	3	3	4	4	4	1	1	
RMD	ResMed Inc.	\$263.55	-6.79	-9.29	6.32	38,898	38,198	0.10	2.51	0.96	3,845	1,318	\$6.43	2	2	3	3	3	4	4	4	4	
SEM	Select Medical Holdings Corporation	\$36.17	2.18	4.63	-14.47	9,226	4,930	0.69	5.44	0.70	6,153	938	\$2.86	2	2	3	3	3	4	4	4	4	
STAA	STAAR Surgical Company	\$128.53	-12.78	-16.79	-14.95	6,164	6,057	1.18	5.47	0.88	276	50	\$0.90	3	3	3	3	3	3	3	3	2	
STE	STERIS PLC	\$204.28	-7.30	-4.99	-2.23	22,030	20,710	1.08	2.70	0.76	4,822	1,351	\$8.20	3	3	3	3	4	4	4	1	1	
TECH	Bio-Techne Corporation	\$484.57	-9.75	-2.92	6.75	20,189	19,377	1.18	1.95	0.97	1,121	444	\$8.05	3	3	3	3	3	3	3	3	2	
TNDM	Tandem Diabetes Care, Inc.	\$119.38	-4.87	6.43	22.34	7,729	7,638	0.71	3.62	0.91	787	123	\$0.62	3	3	3	3	3	4	4	1	1	
TWST	Twist Bioscience Corp.	\$106.97	-11.65	-5.51	-18.64	4,710	5,200	0.33	10.07	0.84	174	-153	-\$3.13	3	3	3	3	3	2	2	2	2	
UJNH	UnitedHealth Group Incorporated	\$390.74	-4.24	-6.13	-3.49	407,854	370,029	0.81	2.24	0.94	301,681	29,247	\$20.91	3	3	3	3	3	3	3	3	2	
VEEV	Veeva Systems Inc Class A	\$288.17	-3.53	-13.20	-8.12	44,554	39,834	0.41	1.28	0.97	2,066	835	\$3.92	3	3	3	3	4	4	4	1	1	
WAT	Waters Corporation	\$357.30	-11.14	-13.70	1.74	23,138	21,827	0.76	5.22	0.87	2,866	976	\$11.40	3	3	3	3	3	4	4	4	1	
WST	West Pharmaceutical Services, Inc.	\$424.54	-6.74	-6.00	16.95	31,517	31,051	0.76	2.38	0.87	2,969	938	\$8.66	3	3	3	3	4	4	4	1	1	
ZTS	Zoetis, Inc. Class A	\$194.14	-5.16	-5.09	2.56	97,270	92,983	0.87	2.82	0.96	8,173	3,595	\$5.00	3	3	3	3	3	4	4	4	4	

Other MicroQuad 3 names of interest include NTRA, one of our top Ideas on the Long side, and we expect the consensus to continue to creep higher, and EYE, which we think has some tailwinds over the remainder of 2021.

# MicroQuad 4 Screen

Good reasons to be short some of these names...

Ticker	Name	Price	MicroQuad 4										Sales MicroQuad									
			1W	1M	3M	EV	MCAP	Beta	Days to Cover	Sales Corr	Sales	EBITDA	EPS	J-21	A-21	S-21	O-21	N-21	D-21	J-22	F-22	M-22
ABBV	AbbVie, Inc.	\$107.87	0.48	-10.69	-5.59	267,307	192,781	0.54	0.97	0.69	58,832	32,312	\$13.56	4	4	4	4	4	4	4	1	1
AMN	AMN Healthcare Services, Inc.	\$114.75	-0.63	1.08	17.28	6,289	5,432	0.76	2.95	0.92	3,039	426	\$4.77	3	3	4	4	4	4	4	1	1
ANTM	Anthem, Inc.	\$372.80	-1.97	-0.62	-2.87	112,043	91,658	1.01	2.04	0.84	147,391	10,061	\$27.84	4	4	4	4	4	4	4	4	4
JNJ	Johnson & Johnson	\$161.50	-2.04	-6.72	-2.69	436,889	422,434	0.34	2.94	0.87	97,096	34,341	\$10.28	3	3	3	4	4	4	4	4	4
MASI	Masimo Corporation	\$270.71	-4.94	-0.31	8.72	14,977	14,891	0.54	6.56	0.97	1,301	400	\$4.27	4	3	4	4	4	4	4	1	1
MRNA	Moderna, Inc.	\$384.86	-15.34	2.17	63.69	139,623	137,680	0.12	1.03	0.90	21,052	15,706	\$28.40	4	4	4	4	4	4	4	4	4
OPCH	Option Care Health Inc	\$24.26	-5.31	-9.31	10.78	5,555	4,464	0.95	1.37	0.67	3,610	304	\$0.81	1	1	1	4	4	4	4	4	4
VRTX	Vertex Pharmaceuticals Incorporated	\$181.39	-2.00	-9.44	-10.30	41,253	46,788	0.33	3.95	0.79	7,840	4,448	\$12.94	4	4	4	4	4	4	4	4	1

AMN should be able to comp the comp, but right now consensus expects significant slowing in 2022. The price however seems to reflect greater optimism than the sell side.

# MicroQuad 1 Screen

Who can make the turn?


MicroQuad 1													Sales MicroQuad									
Ticker	Name	Price	1W	1M	3M	EV	MCAP	Beta	Days to Cover	Sales Corr	Sales	EBITDA	EPS	J-21	A-21	S-21	O-21	N-21	D-21	J-22	F-22	M-22
ABT	Abbott Laboratories	\$118.13	-5.72	-6.52	0.83	219,976	207,792	0.43	2.85	0.95	39,401	11,433	\$4.60	1	1	1	1	3	2	3	3	3
AMED	Amedisys, Inc.	\$149.10	-7.70	-18.72	-42.95	4,960	4,717	0.32	2.09	0.93	2,411	320	\$6.39	1	1	1	1	1	3	2	2	2
AMGN	Amgen Inc.	\$212.65	-1.12	-5.71	-13.87	147,918	121,475	0.60	4.82	0.85	26,866	16,156	\$17.53	1	1	1	1	3	2	3	4	4
BDX	Becton, Dickinson and Company	\$245.82	-3.15	-2.34	-0.38	85,851	70,270	0.29	2.43	0.87	19,485	5,474	\$12.35	1	1	1	3	2	2	2	3	3
DGX	Quest Diagnostics Incorporated	\$145.31	-5.35	-4.92	9.30	22,405	17,509	0.49	4.17	0.78	9,006	1,981	\$9.08	1	1	1	1	1	1	4	4	4
DOCS	Doximity, Inc. Class A	\$80.70	-8.39	-12.28	52.84	13,978	3,878	1.45	1.89	0.91	343	119	\$0.41	1	1	1	1	1	1	1	1	1
ENSG	Ensign Group, Inc.	\$74.89	-1.34	-8.30	-15.72	5,302	4,170	0.43	10.99	0.93	2,789	362	\$3.86	3	1	1	4	2	2	2	2	3
EXAS	Exact Sciences Corporation	\$95.45	-2.82	-8.56	-23.06	17,581	16,533	0.04	9.73	0.82	2,001	-367	-\$2.84	1	1	1	1	4	2	3	3	4
FLGT	Fulgent Genetics, Inc.	\$89.95	2.96	-1.41	2.87	2,247	2,490	-0.93	6.48	0.95	639	0	\$7.78	4	4	1	1	1	1	4	4	4
GKOS	Glaukos Corp	\$48.17	-8.35	-19.22	-42.81	2,201	2,259	1.23	3.24	0.69	272	25	-\$1.28	3	1	1	1	4	2	2	2	3
HOLX	Hologic, Inc.	\$73.81	-4.58	-6.75	8.56	20,988	18,307	0.24	3.57	0.88	3,869	1,387	\$3.69	1	1	1	1	4	2	2	3	3
LH	Laboratory Corporation of America Holdings	\$281.44	-5.16	-7.23	1.24	31,860	27,026	0.79	3.24	0.87	14,353	2,924	\$18.38	1	1	1	1	1	4	4	4	4
LLY	Eli Lilly and Company	\$231.05	-0.49	-10.55	-0.03	222,482	219,621	0.56	2.01	0.89	27,788	9,904	\$8.36	1	1	1	2	2	2	3	3	3
MCK	McKesson Corporation	\$199.38	-1.63	-2.33	3.48	39,035	30,938	1.07	3.06	0.55	255,737	4,772	\$20.76	1	1	1	1	4	3	3	4	4
MRK	Merck & Co., Inc.	\$75.11	2.82	-1.55	-3.69	224,796	206,054	1.17	2.58	0.78	49,862	21,150	\$6.23	1	1	1	1	2	2	2	3	3
NEO	NeoGenomics, Inc.	\$48.24	-3.40	-0.78	7.49	6,381	5,955	0.65	9.24	0.95	560	24	-\$0.17	1	1	1	1	2	2	2	2	2
OPK	OPKO Health, Inc.	\$3.65	-5.93	-5.44	-13.92	2,501	2,439	0.98	14.14	0.59	1,285	108	-\$0.04	1	1	1	1	1	1	1	1	4
PKI	PerkinElmer, Inc.	\$173.29	-6.87	-6.23	12.09	21,484	19,463	0.65	4.56	0.94	4,138	1,173	\$7.20	1	1	1	1	1	1	1	4	4
PRSC	ModivCare Inc.	\$181.62	5.09	-7.93	4.46	2,889	2,617	0.81	2.97	0.86	2,159	188	\$6.48	4	1	1	3	2	2	3	3	4
QDEL	Quidel Corporation	\$141.15	-8.03	9.46	9.76	5,243	5,593	-0.94	7.07	0.80	774	296	\$5.28	1	1	1	1	2	2	3	3	3
SYK	Stryker Corporation	\$263.72	-4.50	-4.83	0.39	113,371	101,145	1.07	3.71	0.96	18,273	5,279	\$10.19	1	1	1	4	2	2	3	3	3
TDOC	Teladoc Health, Inc.	\$126.81	-8.64	-12.19	-22.98	20,261	20,178	0.61	9.35	0.79	2,442	361	-\$1.93	4	1	1	1	2	2	3	3	4
TMO	Thermo Fisher Scientific Inc.	\$571.33	-6.07	2.95	12.13	238,540	225,319	0.45	2.40	0.97	37,670	10,990	\$21.11	1	1	1	4	2	3	3	4	4

MicroQuad 1 is a holding place where companies have two paths; reaccelerate and convert into MicroQuad 2 and emerge as a long, or regress to deceleration and descend into MicroQuad 4. Looking out a couple of months and AMED, ENSG, and NEO are in the accelerate to MicroQuad 2 camp. On the other side, DGX, FLGT, LH, PKI, and to a lesser extent EXAS, are heading for 1Q22 deceleration, and MicroQuad 4.


# Position Monitor | October 1, 2021

HEDGEYE

## Sigma Positioning – Current Position Monitor



## Sigma Positioning – Universe Average



# MicroQuad Model Portfolio

HEDGEYE

Wrap up for the week of 10/1/2021



Percentage Change	WoW	MoM	YTD	YoY	Annualized since 2015
MicroQuad Model Portfolio	-1.2%	-0.5%	9.7%	17.0%	15.4%
XLV	-3.5%	-7.0%	12.2%	22.2%	9.6%
XBI	-3.2%	-6.0%	-10.4%	14.3%	10.9%
XHS	-2.0%	-7.3%	8.0%	35.0%	9.7%
SP50	-2.2%	-3.9%	16.0%	30.1%	11.7%

For the week ending 10/1/2021, the model portfolio was down -1.2% WoW. There were 65 longs and 32 shorts, not much changed week over week. The batting average for the longs was 10.7% while the shorts had a batting average of 68%, very similar to the week prior.


Macro Quad	Micro Quad			
	1	2	3	4
1	-30%	80%	30%	-10%
2	<b>-40%</b>	<b>80%</b>	<b>30%</b>	<b>-10%</b>
3	-50%	70%	20%	-10%
4	-60%	70%	20%	-10%

Depending on the Macro Quad, we target the following long and short exposures by MicroQuad in the Model Portfolio. We currently distribute the screened longs and shorts according to a Macro Quad 3 allocation detailed in the table above.

# MicroQuad | S&P 500 Sector Trends

HEDGEYE

Slope of the consensus NTM estimate trend, Real Estate leading



For more information, contact us at”

**support@hedgeye.com**